Can inhaled insulin be used for the treatment of diabetes mellitus?

References

• Banting FG, Best CH, Collip JB et al. Pancreatic extracts in the treatment of diabetes mellitus. 1922. Indian J. Med. Res.12(1), 141–146 (2007).
   Google Scholar
• Stamler J, Vaccaro O, Neaton JD et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care16(2), 434–444 (1993).
   PubMed Web of Science ®Google Scholar
• [No authors listed]. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med.329(14), 977–986 (1993).
   Google Scholar
• [No authors listed]. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet352(9131), 837–853 (1998).
   Google Scholar
• Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes. N. Engl. J. Med.353(25), 2643–2653 (2005).
   PubMed Web of Science ®Google Scholar
• Saaddine JB, Cadwell B, Gregg EW et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988–2002. Ann. Intern. Med.144(7), 465–474 (2006).
   PubMed Web of Science ®Google Scholar
• Mollema ED, Snoek FJ, Heine RJ et al. Phobia of self-injecting and self-testing in insulin-treated diabetes patients: opportunities for screening. Diabet. Med.18(8), 671–674 (2001).
   PubMed Web of Science ®Google Scholar
• Zambanini A, Newson RB, Maisey M et al. Injection related anxiety in insulin-treated diabetes. Diabetes Res. Clin. Pract.46(3), 239–246 (1999).
   PubMed Web of Science ®Google Scholar
• Owens DR. New horizons – alternative routes for insulin therapy. Nat. Rev. Drug Discov.1(7), 529–540 (2002).
   PubMed Web of Science ®Google Scholar
• Gaensslen M. Ueber inhalation von insulin. Klin. Wochenschr.2, 71–72 (1925).
   Google Scholar
• Wigley FW, Londono JH, Wood SH et al. Insulin across respiratory mucosae by aerosol delivery. Diabetes20(8), 552–556 (1971).
   PubMed Web of Science ®Google Scholar
• Laube BL. Treating diabetes with aerosolized insulin. Chest120(Suppl. 3), S99–S106 (2001).
   PubMed Web of Science ®Google Scholar
• Patton JS, Bukar J, Nagarajan S. Inhaled insulin. Adv. Drug Deliv. Rev.35(2–3), 235–247 (1999).
   PubMed Web of Science ®Google Scholar
• Rave K, Bott S, Heinemann L et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care28(5), 1077–1082 (2005).
   PubMed Web of Science ®Google Scholar
• Schulz H. Mechanisms and factors affecting intrapulmonary particle deposition: implications for efficient inhalation therapies. Pharm. Sci. Technol. Today1(8), 336–344 (1998).
   Google Scholar
• Henry RR, Mudaliar SR, Howland WC 3rd et al. Inhaled insulin using the AERx insulin diabetes management system in healthy and asthmatic subjects. Diabetes Care26(3), 764–769 (2003).
   PubMed Web of Science ®Google Scholar
• Rave K, de la Pena A, Tibaldi FS et al. AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability. Diabetes Care30(7), 1777–1782 (2007).
   PubMed Web of Science ®Google Scholar
• Lange P, Parner J, Schnohr P et al. Copenhagen City Heart Study: longitudinal analysis of ventilatory capacity in diabetic and nondiabetic adults. Eur. Respir. J.20(6), 1406–1412 (2002).
   PubMed Web of Science ®Google Scholar
• Ramirez LC, Dal Nogare A, Hsia C et al. Relationship between diabetes control and pulmonary function in insulin-dependent diabetes mellitus. Am. J. Med.91(4), 371–376 (1991).
   PubMed Web of Science ®Google Scholar
• Hsia CC, Raskin CP. The diabetic lung: relevance of alveolar microangiopathy for the use of inhaled insulin. Am. J. Med.118(3), 205–211 (2005).
   PubMed Web of Science ®Google Scholar
• Himmelmann A, Jendle J, Mellen A et al. The impact of smoking on inhaled insulin. Diabetes Care26(3), 677–682 (2003).
   PubMed Web of Science ®Google Scholar
• Becker RH, Sha S, Frick AD et al. The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. Diabetes Care29(2), 277–282 (2006).
   PubMed Web of Science ®Google Scholar
• Wise S, Chien J, Yeo K et al. Smoking enhances absorption of insulin but reduces glucodynamic effects in individuals using the Lilly-Dura inhaled insulin system. Diabet. Med.23(5), 510–515 (2006).
   PubMed Web of Science ®Google Scholar
• Milton A, Fountaine RJ, Wei G et al. Inhaled insulin – single-dose pharmacokinetics of inhaled human insulin (Exubera®) after acute passive cigarette smoke exposure. Diabetologia49, A615–A616 (2006) (Abstract).
   Google Scholar
• Skyler JS, Weinstock RS, Raskin P et al. Use of inhaled insulin in a basal/bolus insulin regimen in Type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care28(7), 1630–1635 (2005).
   PubMed Web of Science ®Google Scholar
• Quattrin T, Belanger A, Bohannon NJ et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with Type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care27(11), 2622–2627 (2004).
   PubMed Web of Science ®Google Scholar
• Tamborlane WV, Bonfig W, Boland E. Recent advances in treatment of youth with Type 1 diabetes: better care through technology. Diabet. Med.18(11), 864–870 (2001).
   PubMed Web of Science ®Google Scholar
• Rave KM, Nosek L, de la Pena A et al. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care28(10), 2400–2405 (2005).
   PubMed Web of Science ®Google Scholar
• Brunner GA, Balent B, Ellmerer M et al. Dose-response relation of liquid aerosol inhaled insulin in Type I diabetic patients. Diabetologia44(3), 305–308 (2001).
   PubMed Web of Science ®Google Scholar
• Steiner S, Pfutzner A, Wilson BR et al. Technosphere/Insulin – proof of concept study with a new insulin formulation for pulmonary delivery. Exp. Clin. Endocrinol. Diabetes110(1), 17–21 (2002).
   PubMed Web of Science ®Google Scholar
• Skyler JS, Cefalu WT, Kourides IA et al. Efficacy of inhaled human insulin in Type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet357(9253), 331–335 (2001).
   PubMed Web of Science ®Google Scholar
• Skyler JS, Jovanovic L, Klioze S et al. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with Type 1 diabetes. Diabetes Care30(3), 579–585 (2007).
   PubMed Web of Science ®Google Scholar
• Heise T, Bott S, Tusek C et al. The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study. Diabetes Care28(9), 2161–2169 (2005).
   PubMed Web of Science ®Google Scholar
• Weiss SR, Cheng SL, Kourides IA et al. Inhaled insulin provides improved glycemic control in patients with Type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial. Arch. Intern. Med.163(19), 2277–2282 (2003).
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Zinman B, Murphy LJ et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in Type 2 diabetes: a randomized, controlled trial. Ann. Intern. Med.143(8), 549–558 (2005).
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Bergenstal RM, Cefalu WT et al. Efficacy of inhaled insulin in patients with Type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care28(8), 1922–1928 (2005).
   PubMed Web of Science ®Google Scholar
• Barnett AH, Dreyer M, Lange P et al. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with Type 2 diabetes poorly controlled on metformin. Diabetes Care29(8), 1818–1825 (2006).
   PubMed Web of Science ®Google Scholar
• Barnett AH, Dreyer M, Lange P et al. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with Type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care29(6), 1282–1287 (2006).
   PubMed Web of Science ®Google Scholar
• Barnett AH, Lange P, Dreyer M et al. Long-term tolerability of inhaled human insulin (Exubera) in patients with poorly controlled Type 2 diabetes. Int. J. Clin. Pract.61(10), 1614–1625 (2007).
   PubMed Web of Science ®Google Scholar
• Cappelleri JC, Cefalu WT, Rosenstock J et al. Treatment satisfaction in Type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clin. Ther.24(4), 552–564 (2002).
   PubMed Web of Science ®Google Scholar
• Hollander PA, Blonde L, Rowe R et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with Type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care27(10), 2356–2362 (2004).
   PubMed Web of Science ®Google Scholar
• Norwood P, Dumas R, Cefalu W et al. Randomized study to characterize glycemic control and short-term pulmonary function in patients with Type 1 diabetes receiving inhaled human insulin (exubera). J. Clin. Endocrinol. Metab.92(6), 2211–2214 (2007).
   PubMed Web of Science ®Google Scholar
• Garg S, Rosenstock J, Silverman BL et al. Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with Type 1 diabetes. Diabetologia49(5), 891–899 (2006).
   PubMed Web of Science ®Google Scholar
• Hermansen K, Ronnemaa T, Petersen AH et al. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with Type 2 diabetes. Diabetes Care27(1), 162–167 (2004).
   PubMed Web of Science ®Google Scholar
• Boss AH, Evans SH, Ren H et al. Superior post prandial glucose control in patients with Type 1 diabetes when using prandial technosphere insulin compared to NovoLog. Diabetologia49, A114–A115 (2006) (Abstract).
   Google Scholar
• Ceglia L, Lau J, Pittas AG. Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann. Intern. Med.145(9), 665–675 (2006).
   PubMed Web of Science ®Google Scholar
• Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of Type 2 diabetic patients. Diabetes Care26(11), 3080–3086 (2003).
   PubMed Web of Science ®Google Scholar
• Raskin PR, Hollander PA, Lewin A et al. Basal insulin or premix analogue therapy in Type 2 diabetes patients. Eur. J. Intern. Med.18(1), 56–62 (2007).
   PubMed Web of Science ®Google Scholar
• Garber AJ, Wahlen J, Wahl T et al. Attainment of glycaemic goals in Type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1–2–3 Study). Diabetes Obes. Metab.8(1), 58–66 (2006).
   PubMed Web of Science ®Google Scholar
• Hausmann M, Dellweg S, Osborn C et al. Inhaled insulin as adjunctive therapy in subjects with Type 2 diabetes failing oral agents: a controlled proof-of-concept study. Diabetes Obes. Metab.8(5), 574–580 (2006).
   PubMed Web of Science ®Google Scholar
• Royle P, Waugh N, McAuley L et al. Inhaled insulin in diabetes mellitus. Cochrane Database Syst. Rev.3, CD003890 (2003).
   Google Scholar
• Hollander PA, Krasner A, Klioze S et al. Body weight changes associated with insulin therapy: a retrospective pooled analysis of inhaled human insulin (Exubera®) versus subcutaneous insulin in five controlled Phase 3 trials. Diabetes Care30(10), 2508–2510 (2007).
   PubMed Web of Science ®Google Scholar
• Brain JD. Unlocking the opportunity of tight glycaemic control. Inhaled insulin: safety. Diabetes Obes. Metab.7(Suppl. 1), S14–S18 (2005).
   PubMed Web of Science ®Google Scholar
• Camus P. Effect of intercurrent respiratory tract infections on inhaled human insulin (Exubera®) therapy: a retrospective pooled analysis of controlled Phase 2 and 3 trials. Diabetologia49, A616 (2006) (Abstract).
   Google Scholar
• Gern JE, Stone CK, Nakano M et al. Effect of upper respiratory tract infection on AIR inhaled insulin pharmacokinetics and glucodynamics in healthy subjects. Mol. Ther.83(2), 307–311 (2008).
   Google Scholar
• McElduff A, Mather LE, Kam PC et al. Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERx insulin diabetes management system. Br. J. Clin. Pharmacol.59(5), 546–551 (2005).
   PubMed Web of Science ®Google Scholar
• Dreyer M. Efficacy and two-year pulmonary safety of inhaled insulin as adjunctive therapy with metformin or glibenclamide in Type 2 diabetes patients poorly controlled with oral monotherapy. Diabetologia47, A44–A45 (2004) (Abstract).
   Google Scholar
• Skyler JS. Sustained long-term efficacy and safety of inhaled insulin during 4 years of continuous therapy. Diabetes53,A115 (2004) (Abstract).
   Web of Science ®Google Scholar
• Fineberg SE, Kawabata T, Finco-Kent D et al. Antibody response to inhaled insulin in patients with Type 1 or Type 2 diabetes. An analysis of initial Phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J. Clin. Endocrinol. Metab.90(6), 3287–3294 (2005).
   PubMed Web of Science ®Google Scholar
• Freemantle N, Blonde L, Duhot D et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with Type 2 diabetes. Diabetes Care28(2), 427–428 (2005).
   PubMed Web of Science ®Google Scholar
• Testa MA, Simonson DC. Satisfaction and quality of life with premeal inhaled versus injected insulin in adolescents and adults with Type 1 diabetes. Diabetes Care30(6), 1399–1405 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Cappelleri JC, Bolinder B et al. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with Type 1 or Type 2 diabetes. Diabetes Care27(6), 1318–1323 (2004).
   PubMed Web of Science ®Google Scholar
• Gerber RA, Cappelleri JC, Kourides IA et al. Treatment satisfaction with inhaled insulin in patients with Type 1 diabetes: a randomized controlled trial. Diabetes Care24(9), 1556–1559 (2001).
   PubMed Web of Science ®Google Scholar
• Black C, Cummins E, Royle P et al. The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation. Health Technol. Assess.11(33), 1–126 (2007).
   PubMed Web of Science ®Google Scholar
• Freemantle N, Strack TR. Will availability of inhaled human insulin (Exubera) improve management of Type 2 diabetes? The design of the Real World trial. Trials7, 25 (2006).
   PubMed Web of Science ®Google Scholar
• Woo VC, ES Group. Availability of inhaled insulin (Exubera) as a treatment option increases insulin initiation and improves glycemic control in people with Type 2 diabetes: the EXPERIENCE Trial. Can. J. Diabetes31(3), 266 (2007) (Abstract).
   Google Scholar
• Mack GS. Pfizer dumps Exubera. Nat. Biotechnol.25(12), 1331–1332 (2007).
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Barnett AH. Why is Exubera being withdrawn? Br. Med. J.335(7630), 1156 (2007).
   Web of Science ®Google Scholar
• Standards of medical care in diabetes – 2007. Diabetes Care30(Suppl. 1), S4–S41 (2007).
   Google Scholar